[ 메디채널 김갑성 기자 ] KAWASAKI, Japan and NEW TAIPEI CITY, July 18, 2025 -- Fujitsu Limited and Acer Medical Inc., a provider of AI-powered medical imaging and preventative medicine, today announced a collaborative agreement to develop "aiGait" powered by Uvance, a solution that leverages Fujitsu's advanced skeleton recognition AI technology to detect gait pattern abnormalities, and provide gait quantization to healthcare professionals to support the early diagnosis of dementia and Parkinson's disease. The technology is part of "Fujitsu Kozuchi for Vision" from the Fujitsu Uva
NEW YORK, July 17, 2025 -- Lifezoom, a pioneer of red light therapy in the USA, is excited to expand with the new industry-leading Veyra Series, red light therapy panels that mix creativity, adaptability, and health-focused design. Now, with two launch products, Veyra C and Veyra S, this versatile red light technology, built on a flexible silicone base material, is available throughout the U.S and Europe at the starting price of $249. After years of research and development, the Lifezoom engineering team from Iowa's hardworking community has brought to market a product that not
SYDNEY, July 17, 2025 -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT) led by Prof Louise Emmett at St Vincent's Hospital Sydney has now completed study enrolment, with all participants having been imaged. The study is evaluating the performance of Clarity's diagnostic product, 64Cu-SAR-b
[ 메디채널 김갑성 기자 ] Recognized for driving operational efficiency and accelerating customer acquisition through AI-powered automation and a highly adaptive deployment model SAN ANTONIO, July 17, 2025 -- Frost & Sullivan is pleased to announce that RapidClaims has been recognized with the 2025 North American Healthcare IT-Software and Services Technology Innovation Leadership Recognition in the healthcare IT industry for its outstanding achievements in product innovation, operational excellence, and customer-centric design in the revenue cycle management (RCM) space. This recognition
Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant Interim results from the Phase 1/2 trial expected by 2027, aimed at entering the high-immunogenicity vaccine market "Our SKYCellflu platform with our adjuvanted vaccine experience will lay a strong foundation for future success." SEONGNAM, South Korea, July 17, 2025 -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company has submitted an In
MILAN, July 17, 2025 -- A recently published five-year pharmacovigilance study confirms the excellent safety profile of a fixed-dose combination eye drop containing an anti-inflammatory steroid and a quinolone antibiotic, developed by NTC, indicated for the prevention and treatment of inflammation and prevention of infection following cataract surgery in adults. The study was submitted when nearly 4 million patients across about 60 countries worldwide were treated with this drug. Conducted by Italian researchers and supported by NTC, the study analyzed public safety data registered in
밀라노, 2025년 7월 17일 -- 최근 발표된 5년간의 약물감시 시험에서 NTC가 개발한 항염증성 스테로이드와 퀴놀론계 항생제가 함유된 고정용량 병용 점안제가 탁월한 안전성을 보이는 것으로 확인됐다. 특히 성인의 백내장 수술 후 염증 예방 및 치료와 감염 예방에 적합하다. 이 시험은 약 60개국에서 약 400만 명의 환자가 이 약물을 사용한 데이터를 기반으로 이루어졌다. 이탈리아 연구진이 수행하고 NTC의 지원을 받은 이 시험은 유럽 의약품청(European Medicines Agency)의 공식 약물 부작용(ADR) 데이터베이스인 EudraVigilance에서 안전성 보고서를 수집하는 adrreports.eu 포털에 등록된 공공 안전 데이터를 분석했다. 이 시험에서 2020년과 2024년 사이 해당 약물과 관련된 ADR은 총 25명의 환자에서 53건만 보고됐다. 주요 결과는 다음과 같다. ADR의 74%는 중대하지 않았다. 절반 이상이 해당 약물과 관련성이 낮은 것으로 판단됐다. 가장 빈번하게 보고된 사례는 눈 또는 피부와 관련된 경미한 반응으로, 이는 국소 투여되는 안과용 점안액에서 예상 가능한 결과로 여겨진
KUALA LUMPUR, Malaysia, July 17, 2025 -- In celebration of World Microbiome Day, SpaceGut, a Malaysia-based health tech company, introduces a scientific and personalised approach to one of the country's most pressing health concerns, obesity. Through its Gut Microbiome Test Kit and AI-powered personalised meal plan, SpaceGut aims to address the root microbial imbalances that contribute to excessive weight gain and metabolic disorders. Obesity in Malaysia has become an increasingly serious public health concern. According to the National Health and Morbidity Survey (NHMS) 2023,
SINGAPORE, July 17, 2025 -- At the Growth Asia Summit 2025, which took place from July 15–17 in Singapore, Vinamilk was honored to be the only Vietnamese company invited as a keynote speaker. The Growth Asia Summit is the largest forum for growth opportunities in the food, beverage, and nutrition industries in Asia. The brand made a remarkable impression with its innovative 6-HMO infant formula, setting a new standard in pediatric nutrition and paving the way for the dairy industry in Asia. Vinamilk's presence at the Summit is symbolic; it reflects the nation's transformation f
[ 메디채널 김갑성 기자 ] 선전, 중국 2025년 7월 17일 -- 화웨이(Huawei)가 '2025 글로벌 교육 및 의료 파트너 중국 컨벤션(2025 Global Education and Healthcare Partner China Convention)'을 개최했다. 이번 행사에는 40개국에서 300명 이상의 협력사 관계자들이 참석했다. 이 자리에서 화웨이는 글로벌 교육 및 헬스케어 파트너 연합(Global Education and Healthcare Partner Alliance, GEHPA)을 공식 출범했다. 연합은 업계 파트너들과의 소통을 강화하고, 상호 강점을 결합해 상생 협력을 도모하며, 궁극적으로는 고품질의 지속 가능한 산업 생태계 구축을 목표로 한다. GEHPA 참여 기관들은 공동으로 기술 연구를 수행하고, 혁신적인 솔루션을 개발해 전 세계 교육 및 의료 분야의 디지털 전환을 가속할 수 있을 것으로 기대된다. AI 기술과 애플리케이션이 급속도로 발전하면서 교육과 의료 분야에 큰 영향을 미치고 있다. 화웨이 엔터프라이즈 영업부 파트너 개발 및 상업•유통 사업부 어니스트 장(Ernes